Monoclonal Antibody Therapy in Kidney Transplant Recipients With Delta and Omicron Variants of SARS-CoV-2: A Single-Center Case Series

被引:13
作者
Fernandes, Guillaume [1 ]
Devresse, Arnaud [1 ,5 ]
Scohy, Anais [2 ]
De Greef, Julien [3 ]
Yombi, Jean Cyr [3 ]
Belkhir, Leila [3 ]
Darius, Tom [4 ]
Mourad, Michel [4 ]
Buemi, Antoine [4 ]
Kabamba, Benoit [2 ]
Goffin, Eric [1 ]
Kanaan, Nada [1 ]
机构
[1] Catholic Univ Louvain, Clin Univ St Luc, Div Nephrol, Brussels, Belgium
[2] Catholic Univ Louvain, Div Microbiol, Clin Univ St Luc, Brussels, Belgium
[3] Catholic Univ Louvain, Internal Med & Infect Dis, Clin Univ St Luc, Brussels, Belgium
[4] Catholic Univ Louvain, Clin Univ St Luc, Brussels, Belgium
[5] Clin Univ St Luc, Ave Hippocrate,10, B-1200 Brussels, Belgium
关键词
INFECTION;
D O I
10.1016/j.xkme.2022.100470
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Rationale & Objective: Neutralizing monoclonal antibody treatments have shown promising pre-liminary results in kidney transplant recipients infected with severe acute respiratory syndrome coronavirus 2. However, their efficacy in kidney transplant recipients infected with the Omicron variant has not been reported yet. Study Design: Single-center retrospective study. Setting & Participants: We included all consecutive kidney transplant recipients treated with monoclonal antibodies for severe acute respiratory syndrome coronavirus 2 infections (positive poly-merase chain reaction on nasopharyngeal swab) between June 10, 2021, and January 14, 2022. Forty-seven kidney transplant recipients were included. All patients had symptoms evolving for <= 7 days and no oxygen therapy need at monoclonal antibody infusion. Results: Symptoms at diagnosis were mainly cough (n = 25; 53%) and fever (n = 15; 32%). Eighty-three percent of the cohort (n = 39) had been vaccinated with at least 2 doses before infection, of whom 30 (77%) had demonstrated a vaccine-induced humoral response. They were treated with either casirivimab-imdevimab (n = 16; 34%) or sotrovimab (n = 31; 66%) a median of 2 days (range, 0-6 days) after the onset of symptoms. Except for 1 mild allergic reaction during casirivimab-imdevimab infusion, no side effects were reported. The median viral loads at admission (day 0) and 7 days after monoclonal antibody infusion were 2,110,027 copies/mL (range, 1,000-153,798,9 62 copies/mL) and 1,000 copies/mL (range, 0-10,000,000 copies/mL), respectively. Genotypes were available for 22 kidney transplant recipients (47%). Omicron, Delta, and Gamma variants were identified in 13 (59%), 8 (36%), and 1 (5%) patients, respectively. In kidney transplant recipients infected with the Omicron variant, the median viral loads at day 0 and day 7 were 752,789 copies/mL (range, 4,000-12,859,3 00 copies/mL) and 1,353 copies/mL (range, 0-1,211,163 copies/mL), respectively. 2 kidney transplant recipients required hospitalization immediately after sotrovimab perfusion for oxygen therapy that was weaned in 3 days, allowing patients' discharge. None were admitted to the intensive care unit or died. Limitations: Small sample size, no control group. Conclusions: Neutralizing monoclonal antibody therapy is associated with positive outcomes in kidney transplant recipients with mild coronavirus disease 2019, including those infected with the Omicron variant.
引用
收藏
页数:7
相关论文
共 33 条
  • [21] Use of anti-spike monoclonal antibodies in kidney transplant recipients with COVID-19: Efficacy, ethnic and racial disparities
    Klein, Elizabeth J.
    Hardesty, Anna
    Vieira, Kendra
    Farmakiotis, Dimitrios
    [J]. AMERICAN JOURNAL OF TRANSPLANTATION, 2022, 22 (02) : 640 - 645
  • [22] Lee K, 2009, GLOB INST, P1
  • [23] Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement
    McCallum, Matthew
    Czudnochowski, Nadine
    Rosen, Laura E.
    Zepeda, Samantha K.
    Bowen, John E.
    Walls, Alexandra C.
    Hauser, Kevin
    Joshi, Anshu
    Stewart, Cameron
    Dillen, Josh R.
    Powell, Abigail E.
    Croll, Tristan, I
    Nix, Jay
    Virgin, Herbert W.
    Corti, Davide
    Snell, Gyorgy
    Veesler, David
    [J]. SCIENCE, 2022, 375 (6583) : 864 - +
  • [24] Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2
    McDonald, Ian
    Murray, Sam M.
    Reynolds, Catherine J.
    Altmann, Daniel M.
    Boyton, Rosemary J.
    [J]. NPJ VACCINES, 2021, 6 (01)
  • [25] Subcutaneous REGEN-COV Antibody Combination to Prevent Covid-19
    O'Brien, M. P.
    Forleo-Neto, E.
    Musser, B. J.
    Isa, F.
    Chan, K-C
    Sarkar, N.
    Bar, K. J.
    Barnabas, R., V
    Barouch, D. H.
    Cohen, M. S.
    Hurt, C. B.
    Burwen, D. R.
    Marovich, M. A.
    Hou, P.
    Heirman, I
    Davis, J. D.
    Turner, K. C.
    Ramesh, D.
    Mahmood, A.
    Hooper, A. T.
    Hamilton, J. D.
    Kim, Y.
    Purcell, L. A.
    Baum, A.
    Kyratsous, C. A.
    Krainson, J.
    Perez-Perez, R.
    Mohseni, R.
    Kowal, B.
    DiCioccio, A. T.
    Stahl, N.
    Lipsich, L.
    Braunstein, N.
    Herman, G.
    Yancopoulos, G. D.
    Weinreich, D. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (13) : 1184 - 1195
  • [26] Risk of Breakthrough SARS-CoV-2 Infections in Adult Transplant Recipients
    Qin, Caroline X.
    Moore, Linda W.
    Anjan, Shweta
    Rahamimov, Ruth
    Sifri, Costi D.
    Ali, Nicole M.
    Morales, Megan K.
    Tsapepas, Demetra S.
    Basic-Jukic, Nikolina
    Miller, Rachel A.
    van Duin, David
    Santella, Robert N.
    Wadei, Hani M.
    Shah, Pali D.
    Gage, Nikki
    Malinis, Maricar
    Aslam, Saima
    Todesco, Eve
    Werbel, William A.
    Avery, Robin K.
    Segev, Dorry L.
    [J]. TRANSPLANTATION, 2021, 105 (11) : E265 - E266
  • [27] Monoclonal antibody treatment for COVID-19 in solid organ transplant recipients
    Sarrell, Bonnie Ann
    Bloch, Karen
    El Chediak, Alissar
    Kumm, Kayla
    Tracy, Kaitlyn
    Forbes, Rachel C.
    Langone, Anthony
    Thomas, Lora
    Schlendorf, Kelly
    Trindade, Anil J.
    Perri, Roman
    Wright, Patty
    Concepcion, Beatrice P.
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2022, 24 (01)
  • [28] Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial
    Self, Wesley H.
    Sandkovsky, Uriel
    Reilly, Cavan S.
    Vock, David M.
    Gottlieb, Robert L.
    Mack, Michael
    Golden, Kevin
    Dishner, Emma
    Vekstein, Andrew
    Ko, Emily R.
    Der, Tatyana
    Franzone, John
    Almasri, Eyad
    Fayed, Mohamed
    Filbin, Michael R.
    Hibbert, Kathryn A.
    Rice, Todd W.
    Casey, Jonathan D.
    Hayanga, J. Awori
    Badhwar, Vinay
    Leshnower, Bradley G.
    Sharifpour, Milad
    Knowlton, Kirk U.
    Peltan, Ithan D.
    Bakowska, Elizieta
    Kowalska, Justyna
    Bowdish, Michael E.
    Sturek, Jeffrey M.
    Rogers, Angela J.
    Files, D. Clark
    Mosier, Jarrod M.
    Gong, Michelle N.
    Douin, David J.
    Hite, R. Duncan
    Trautner, Barbara W.
    Jain, Mamta K.
    Gardner, Edward M.
    Khan, Akram
    Jensen, Jens-Ulrik
    Matthay, Michael A.
    Ginde, Adit A.
    Brown, Samuel M.
    Higgs, Elizabeth S.
    Pett, Sarah
    Weintrob, Amy C.
    Chang, Christina C.
    Murrary, Daniel D.
    Gunthard, Huldrych F.
    Moquete, Ellen
    Grandits, Greg
    [J]. LANCET INFECTIOUS DISEASES, 2022, 22 (05) : 622 - 635
  • [29] An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by therapeutic monoclonal antibodies
    VanBlargan, Laura A.
    Errico, John M.
    Halfmann, Peter J.
    Zost, Seth J.
    Crowe, James E., Jr.
    Purcell, Lisa A.
    Kawaoka, Yoshihiro
    Corti, Davide
    Fremont, Daved H.
    Diamond, Michael S.
    [J]. NATURE MEDICINE, 2022, 28 (03) : 490 - +
  • [30] REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19
    Weinreich, D. M.
    Sivapalasingam, S.
    Norton, T.
    Ali, S.
    Gao, H.
    Bhore, R.
    Xiao, J.
    Hooper, A. T.
    Hamilton, J. D.
    Musser, B. J.
    Rofail, D.
    Hussein, M.
    Im, J.
    Atmodjo, D. Y.
    Perry, C.
    Pan, C.
    Mahmood, A.
    Hosain, R.
    Davis, J. D.
    Turner, K. C.
    Baum, A.
    Kyratsous, C. A.
    Kim, Y.
    Cook, A.
    Kampman, W.
    Roque-Guerrero, L.
    Acloque, G.
    Aazami, H.
    Cannon, K.
    Simon-Campos, J. A.
    Bocchini, J. A.
    Kowal, B.
    DiCioccio, A. Thomas
    Soo, Y.
    Geba, G. P.
    Stahl, N.
    Lipsich, L.
    Braunstein, N.
    Herman, G.
    Yancopoulos, G. D.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (23)